Net Cash Provided by (Used in) Financing Activities in USD of Protalix BioTherapeutics, Inc. from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Protalix BioTherapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2010 to Q1 2025.
  • Protalix BioTherapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $5.08M.
  • Protalix BioTherapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was -$16.8M, a 168% decline from 2023.
  • Protalix BioTherapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $24.7M, a 199% increase from 2022.
  • Protalix BioTherapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $8.24M, a 31.8% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Protalix BioTherapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $5.08M Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-09
Q1 2023 $14.2M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q1 2021 $42.1M +$3.51M +9.08% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q1 2020 $38.6M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q1 2017 -$6.73M Jan 1, 2017 Mar 31, 2017 10-Q 2019-03-18
Q1 2012 $25.6M +$4.64M +22.2% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-09
Q1 2011 $20.9M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-09

Protalix BioTherapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$16.8M -$41.5M -168% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-17
2023 $24.7M +$16.4M +199% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-17
2022 $8.24M -$3.84M -31.8% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-17
2021 $12.1M -$34.4M -74% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-14
2020 $46.5M +$46.5M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 $0 +$4.75M Jan 1, 2019 Dec 31, 2019 10-K 2020-03-12
2018 -$4.75M -$3.33M -235% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-30
2017 -$1.42M -$21.1M -107% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 $19.7M +$13.1M +197% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-18
2015 $6.64M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-06
2012 $26.6M +$5.63M +26.9% Jan 1, 2012 Dec 31, 2012 10-K 2013-02-28
2011 $20.9M +$20.4M +4077% Jan 1, 2011 Dec 31, 2011 10-K 2013-02-28
2010 $501K Jan 1, 2010 Dec 31, 2010 10-K 2013-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.